Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 17/20 | 0.50 |
| ▸ | GIPR | P48546 | 4/20 | 0.49 |
| ▸ | VIPR2 | P41587 | 2/20 | 0.49 |
| ▸ | GLP1R | P43220 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.48 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.48 |
| ▸ | DUSP2 | Q05923 | 1/20 | 0.48 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.48 |
| ▸ | GCG | P01275 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15958538 | 0.93 | NPC1 (0.53) | GCGRGCG | |
| SCHEMBL2669963 | 0.90 | GCGR (0.55) | GCGRGIPRVIPR2GLP1RKCNH2 | |
| SCHEMBL15958537 | 0.90 | NPC1 (0.56) | GCGRGCG | |
| SCHEMBL15948158 | 0.86 | GCGR (0.60) | GCGRGIPR | |
| SCHEMBL15958855 | 0.84 | UTS2R (0.46) | UTS2R | |
| SCHEMBL15958534 | 0.84 | GCG (0.53) | GCGRGIPRGCG | |
| SCHEMBL2669859 | 0.83 | GCGR (0.48) | GCGRGIPRVIPR2GLP1RKCNH2 | |
| SCHEMBL9071524 | 0.81 | GCGR (0.53) | GCGRGCG | |
| SCHEMBL9071523 | 0.80 | GCGR (0.43) | GCGRGIPRVIPR2GLP1RKCNH2 | |
| SCHEMBL15948185 | 0.80 | GCGR (0.60) | GCGRGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170143673-A1 | Methods For Treating Heart Failure Using Glucagon Receptor Antagonists | REMD Biotherapeutics, Inc | 2017-05-25 | — | — | US | disclosed |
| US-8809579-B2 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809579-B2 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20110312911-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME CORP. | 2011-12-22 | — | — | US | disclosed |
| US-20110312911-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME CORP. | 2011-12-22 | — | — | US | disclosed |
| WO-2010098948-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAININ SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170143673-A1 | Methods For Treating Heart Failure Using Glucagon Receptor Antagonists | GLP1R, GCGR, GIPR | GCGR 2/4885GIPR 3/4885VIPR2 40/4885 |
| US-20110312911-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | GCGR, GLP1R, GPR119 | GCGR 1/4885GIPR 4/4885VIPR2 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.